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A steady state kinetic analysis of the avian myelo- 
blastosis virus/Rous sarcoma virus (AMV/RSV) and 
human  immunodeficiency virus Type 1 (HIV- 1) retro- 
viral proteases (PRs) was carried  out  using  a series of 
40 peptide  substrates  that  are d rivatives of  the AMVI 
RSV nucleocapsid-PR cleavage site. These peptides 
contain single amino  acid  substitutions  in  each of the 
seven positions  of  the minimum length  substrate re- 
quired by the PR for  specific  and efficient cleavage. 
These  peptide  substrates  are  distinguished by the  in- 
dividual  enzyme  subsites  of  the AMV/RSV and  HIV-1 
PRs. The  molecular basis for similarities and differ- 
ences of the  individual  subsites  for  both  proteases is 
discussed  using  steady state kinetic data  and  modeling 
based  on crystal structures. 
The retroviral protease  (PR)’ is required for production of 
mature, infectious virus particles (1-3). As a result, this 
enzyme is a suitable target for the design of antiviral agents. 
However, rational  drug design has proven to be a formidable 
task since the molecular forces that drive formation of the 
PR-substrate complex are  not fully understood. 
Studies on the activity of PR on peptide substrates have 
shown that  the enzyme requires a t  least I amino acid residues 
for specific and efficient processing. This includes 4 amino 
acid residues on the amino-terminal side and 3 amino acid 
residues on the carboxyl-terminal side of the scissile bond of 
a substrate. These are referred to as P4-Pl and Pl’-P3‘, 
respectively, using the nomenclature of Schechter and Berger 
(4 ) .  Inspection of these 7 residues from a variety of sequences 
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known to be specifically and efficiently processed by PR does 
not reveal a simple consensus sequence. 
Structural analysis of inhibitor complexes of HIV-1 PR (5- 
11) indicates that  the  substrate most likely binds to PR in an 
extended ,6 conformation, maintained by a network of hydro- 
gen bonds between the main chain amide and carbonyl groups 
of the  substrate  and  PR (12, 13). In addition, subsites (S4- 
S3‘) of the substrate-binding pocket have been identified from 
structural  data.  The inhibitors used are generally hydrophobic 
and are capable of interacting with the P3-P3’ residues of 
the substrate. Shown schematically in Fig. 1 is an AMV/RSV 
peptide representing the cleavage site found between the 
AMV/RSV nucleocapsid (NC) and PR proteins (14) and 
referred to as the NC-PR peptide substrate. This peptide 
substrate is depicted as being bound to  the substrate-binding 
pocket. This diagram also emphasizes the relative size and 
position of the S4-S3’ subsites that interact with each sub- 
strate position and  lists amino acids that differ between the 
RSV and  HIV-1 PR subsites. Interestingly, essentially iden- 
tical subsites have been described for the various HIV-1 PR 
complexes despite large differences in the primary structure 
of the substrate-based  inhibitors (5-11). This suggests that 
the subsites  are  constrained by the structure of PR and  to a 
large extent are independent of substrate sequence. This 
hypothesis is supported by data obtained from the analysis of 
AMV/RSV PRs with mutations in the substrate-binding 
pocket that demonstrate that PR subsites are capable of 
acting independently in the selection of substrates (12). Note 
that  the RSV and AMV PRs, which differ in sequence by  two 
amino acids, are biochemically indistinguishable and have 
been used interchangeably in these studies. In order to avoid 
confusion, we will use AMV/RSV throughout to refer to both 
PRs. However, the viral PR was purified from AMV, whereas 
the RSV PR was bacterially produced. 
Previously, we described the activities of AMV/RSV and 
HIV-1 PRs on an AMV/RSV NC-PR peptide substrate that 
was  cleaved specifically and efficiently by both enzymes. In  a 
subsequent report, we characterized the activities of both 
AMV/RSV and  HIV-1 PRs on analogs of the NC-PR peptide 
substrate  that contained single amino acid substitutions be- 
ginning in the P4 position of the substrate and extending 
through the P3’ position (12). This set of systematically 
modified peptides was capable of biochemically distinguishing 
the subsites of these  PRs. In this report, we describe results 
from kinetic analyses of AMV/RSV and  HIV-1 PRs on the 
40 modified NC-PR peptide substrates  and discuss these  data 
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in terms of the molecular basis of PR substrate specificity 
and  catalytic efficiency. Furthermore,  this  study  has  identified 
amino acids in each of the enzyme subsites that may be 
important  determinants  for specific  recognition of substrates. 
EXPERIMENTAL PROCEDURES 
Purification of Retroviral  Proteases-AMV PR, purified  from  virus 
as  described  (15), was obtained  from  Molecular  Genetic  Resources, 
Tampa, FL.  HIV-1  PR  expressed  in and purified  from  bacteria was a 
generous  gift of Dr. J. Giam,  Case  Western  Reserve  University. 
Peptides-The  peptides  used  in this study were synthesized and 
purified by Advanced Chemtech (Louisville, KY). Peptides were 
solubilized  in 1 mM 2-mercaptoethanol, and their concentrations were 
determined by quantitative amino  acid  composition  analysis.  Speci- 
ficity of  cleavage  was established by direct  amino-terminal  analysis 
of  product  peptides (16). 
Assay of PR Activity-The reaction mixture contained 100 mM 
sodium phosphate,  pH  5.9,2.4 M sodium  chloride (1 M sodium  chloride 
was  used  for HIV-1  and  HIV-2 PR reactions), 10-400  pM peptide  as 
indicated,  and 0.5-5  pg/ml  PR. Reaction volumes  were  25 pl. Reac- 
tions were initiated by the addition of PR, incubated for various 
periods of time,  and  stopped by the addition of 175  pl  of  0.5 M sodium 
borate, pH 8.5. Twenty p1 of 0.05% (w/v) fluorescamine was then 
added.  HIV-1  PR was never incubated more than 8 min  due to its 
instability, presumably a result of autodegradation. The relative 
fluorescence, after reaction  with  fluorescamine,  was  determined  on a 
Perkin-Elmer LSdB spectrofluorometer  using  an  excitation wave- 
length of 386  nm and an  emission  wavelength of  477  nm. Excitation 
and emission slit widths  were  10  nm.  Relative  fluorescence intensity 
was  converted to nanomoles of product  using a standard curve  de- 
scribed  by the following equation: nmol of product = relative  fluores- 
cence intensity/313. The standard curve  was obtained  using a hexa- 
peptide  with a free  amino  terminus (14). The concentration of this 
peptide was determined by amino acid composition analysis. The 
peptides used  in this study were  designed  with  prolines at their amino 
termini so that the relative  fluorescence intensity represents only the 
newly formed amino termini produced as a result of proteolytic 
cleavage.  Arginine  residues  were  added to the carboxyl terminus to 
improve  solubility of the peptides. The addition of these  amino  acids 
did  not  influence their kinetic  parameters. 
Steady State Kinetic Amlysis-Kinetic constants were determined 
using the assay  described  above.  Concentrations of peptide  ranged 
from  0.25-4  times the K ,  value.  No  more than 20% of the substrate 
was  allowed to be  consumed during the course of any  given experi- 
ment. Initial velocity data used to calculate  kinetic constants were 
obtained from at least three experiments performed in duplicate. 
Kinetic constants were determined by a nonlinear fit of the data to 
the Michaelis-Menten  equation  using the NFIT program (14). Cor- 
relation  coefficients of the fit were greater than 0.98, and the standard 
deviation of the constants reported was 520%. 
Molecular  Modeling-The crystal structures of the native RSV PR 
(17) and HIV-1 PR, as well as the complexes of the latter with 
inhibitors  (5-9)  were  superimposed  using C, atoms  and  examined  on 
an Evans  and Sutherland ESVlO  computer  graphics  system  using the 
program  FRODO (18). The residues  forming the subsites were deter- 
mined directly for the HIV-1 PR complexed  with inhibitors, and the 
corresponding  residues  in  RSV PR were obtained from the structural 
and sequence alignments (12). The NC-PR substrate was  modeled as 
described  previously (12), and different  amino  acid  side  chains were 
substituted at positions  P4  to  P3'  in  order to provide a structural 
explanation  for the kinetic data. 
RESULTS AND DISCUSSION 
Rationale for Choice of Substitutions in  Peptide Substrates- 
We  have  synthesized 40 different  peptide  substrates,  based 
on  the AMV/RSV NC-PR cleavage site  (PPAVS-LAMTM), 
which contain single amino acid substitutions  in  each of seven 
positions, P4-P3'. The amino acids present in these seven 
positions of the  substrate  have  been  shown by biochemical 
and crystallographic analyses to be necessary  for specific and 
efficient processing by the retroviral PR. The amino acids 
substituted  into  the  NC-PR  peptide were chosen  to  explore 
predictions of size and  polarity of each of the seven  known 
subsites of the PR substrate-binding pocket. For instance, 
Gly, which has  no side chain, was substituted at each position 
to test the importance of substrate side chain interactions 
with  each PR subsite. A number of general features of the 
AMV/RSV subsites were taken  into  account  in designing the 
NC-PR analogues. For example, subsite  S4  is  near  the  protein 
surface SO that it may accommodate a variety of different 
types of substrate side chains.  Subsite  S3  is formed partially 
by the  charged residues, Arg-10 and Arg-105. Subsite S2 is 
small  and hydrophobic, whereas  subsite S1 is large and  hy- 
drophobic. Subsite S1' is medium-sized and hydrophobic, and 
the  natural  substrates  do  not show  a  residue  larger than Leu 
a t  Pl'. Subsite  S2', like S2, is small  and hydrophobic. Subsite 
S3' is near  the  surface of the enzyme and  is  partially exposed 
to solvent. 
The  studies described here utilized peptides as substrates 
in  place of the  multidomain  polyproteins  that  are  substrates 
in uiuo. This  strategy  appears to be valid since  peptides based 
upon the naturally occurring cleavage sites are specifically 
and efficiently  cleaved by the PR of the  virus from which the 
cleavage sites were derived (12, 14, 19-21). Furthermore,  the 
relative efficiencies of processing of various  sites were similar 
for  both polyprotein and  peptide  substrates (22, 23).* 
Steady  State Kinetic  Analysis of the NC-PR Peptide  Ana- 
logues with the AMVIRSV and HIV-l PRs-The steady  state 
kinetic  parameters for  each of the  NC-PR  peptide analogues 
with AMV/RSV or  HIV-1 PRs are  presented  in  Tables I and 
11. The KM and kcat data are presented relative to those 
observed  with  the wild type AMV/RSV NC-PR  substrate.  For 
AMV/RSV PR, the KM is 41.6 FM, kat is 21.6  min", and  the 
calculated kat/KM value  is 0.51 min" p ~ " .  For  HIV-1  PR, 
the KM is 15.8 p ~ ,  the kcat is 43.8 min", and  the  calculated 
kcat/& value is 2.77 min-l. The AMV/RSV NC-PR  substrate 
is one of the most efficiently processed cleavage sites for 
AMV/RSV PR (20). The  HIV-1 PR binds  this  substrate with 
a greater  affinity  than  the  avian enzyme and cleaves it with 
an  overall catalytic efficiency (k,.,/KM) comparable  to  that of 
its homologous substrates (20). The AMV/RSV NC-PR cleav- 
age site  contains relatively small  amino acid side chains  at 
each position, except for leucine a t  P1' and methionine at 
P3'. The existence of small side chains in this substrate 
permits  the  substitution of a wide variety of amino  acids  in 
each  position of the cleavage site  without  the complication of 
forming destabilizing interactions between  residues adjacent 
to  one  another  in  the  substrate-binding pocket, as  noted by 
Tozser et al. (24). Thus,  the NC-PR cleavage site  is well suited 
for  the  studies described below that probe the  interaction of 
individual PR subsites of the AMV/RSV and HIV-1 sub- 
strate-binding  pocket  with  substrate.  We were able  to  perform 
a steady  state  kinetic  analysis  with  the HIV-1 PR using  all of 
the  AMV/RSV  NC-PR  peptide analogues,  with the exception 
of Trp  substituted  in  P2'  and Gly or Asp substituted  in  P3'. 
For AMV/RSV PR, the rate of cleavage was too low for 
reliable kinetic  analysis  with Leu or  Phe  substituted  in P4, 
Pro  in P3, Gly and His in  P2,  Gln  or Gly in Pl', His or Trp 
in P2', and Leu, Asn, Asp, and Gly in  P3'. 
To  provide perspective  on  the very  complex substrate spec- 
ificity of retroviral  PRs,  the sequence of the AMV/RSV NC- 
PR substrate,  together  with  the  amino  acids  found  in  the P4- 
P3' positions of all natural AMV/RSV and HIV-1 gag-pol 
polyprotein-processing  sites  are  listed  in  Table 111. Note  that 
these sequences are not necessarily the best possible sub- 
strates due to the need for regulation of cleavage of the 
polyproteins.  In  many cases, substitutions of more  favorably 
fitting  amino  acids  results  in  increased activity. A comparison 
of the  amino  acids  predicted  to form the seven HIV-1  and 
* C. Cameron and J. Leis,  unpublished  observations. 
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TABLE I 
Comparison of HIV-1 PR kinetic data for AMVIRSV  NC-PR 
substrates with substitutions in the P4-P3' positions 
Varying concentrations of the  NC-PR (PPAVS  LAMTMRR) or 
NC-PR substrates with amino acid substitutions in the P4-P3' 
positions as indicated were incubated with purified HIV-1 PR (6-24 
ng), and  the extent of cleavage was determined using the fluoresca- 
mine assay as described under "Experimental Procedures." The wild 
type  amino acid in  the  NC-PR peptide  is indicated in the parentheses 
in the first column. ND, cleavage products were not detected. This 
would indicate that  the relative catalytic efficiency (kat/&) for these 
reactions was ~0.001. 
Substrate 
position 
Substituted KM Relative 
amino acid k a t a  kt/& 
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The kinetic parameters for the P4-P3'-substituted NC-PR sub- 
strates are given relative to  the unmodified wild type substrate, which 
is defined as equal to 1 in each case. For HIV-1 PR,  the KM is 15.8 
gM, the Lt is 43.8 min", and  the calculated kcat/& value is 2.77 
min". 
~ .~ 
AMV/RSV PR subsites, which highlights the differences be- 
tween the two enzymes, is presented in Table IV and  in Fig. 
1. Note that because the peptide substrate binds in an ex- 
tended ,f3 conformation, alternate subsites, such as S1 and 53, 
are adjacent to one another (Fig. 1). 
Subsite S4"The S4 subsite of HIV-1 PR is located near 
the enzyme surface such that amino acids in the P4 substrate 
position may be partially exposed to surrounding water mol- 
ecules (Fig. 2a). This is consistent with the observation that 
amino acids found  in the P4 position of HIV-1 PR gag and 
pol polyprotein cleavage sites are mostly polar (Table 111). 
Similarly, the S4 subsite of AMV/RSV PR is near the surface. 
However, modeling of this  site  predicts that Pro-62 and Gln- 
63, derived from the flaps, may interact with the side chain 
TABLE I1 
Comparison of AMVIRSV  PR kinetic data for AMVIRSV  NC-PR 
substrates with substitutions in the P4-P3' positions 
Varying concentrations of the same  NC-PR (PPAVS LAMTMRR) 
or NC-PR substrates with amino acid substitutions in the P4-P3' 
positions as indicated were incubated with purified AMVIRSV PR 
(25-100 ng). and steady state kinetic data were analyzed. Table 
notations are  as described in the legend to Table I. 
Substrate Substituted 
position amino  acid kta KM 
Relative 
































































































































































' The kinetic  parameters for the P4-P3'-substituted NC-PR sub- 
strates are given relative to  the unmodified wild type substrate, which 
is defined as equal to 1 in each case. For AMV PR,  the KM is 41.6 
pM, ht is 21.6  min", and  the calculated kat/& value is 0.51  min" 
NM". 
of the P4 amino acid (12) (Fig. 2a). These additional amino 
acid residues in AMV/RSV PR provide for a more enclosed 
S4 subsite, capable of accommodating hydrophobic residues. 
This is consistent with the observation that mostly small 
hydrophobic amino acids residues are found in the AMV/ 
RSV gag and pol polyprotein cleavage sites at this position 
(Table 111). When residues 61-63 are deleted from AMV/RSV 
PR, the avian enzyme utilizes substrates with polar residues 
(Asn or His) in P4 similarly to HIV-1 PR.3 This conclusion 
that  the AMV/RSV PR  S4 subsite  is more enclosed than  the 
HIV-1 PR  S4 subsite is further  supported by the kinetic data 
summarized in  Tables I and 11, which demonstrate that HIV- 
1 PR is less sensitive to changes in the P4 position than 
C. Cameron, T. Ridky, J. Leis, H. Burstein, A. M. Skalka, 1. 
Weber, T. Copeland, and A. Wlodawer, manuscript in preparation. 
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TABLE 111 
Amino acid residues in gag and pol AMVIRSV and HIV-I protease cleavage sites 
The amino acid sequence in bold letters represents the AMV/RSV NC-PR cleavage site. Numbers in  parentheses indicate the multiple of 
times the amino acid is found in  the  natural gag and pol cleavage sites. 
Amino acids required for cleavage 
Virus P4 P3 P2 P1 
Pro Ala Val 
P1‘ P2 ‘ P3 ’ 
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Comparison of the amino acid residues forming  the subsites of the AMVIRSV and HIV-1 proteases 
Subsite Amino  acid  re idues” RSV/HIV protease residuesb 
s 4  Nonconserved I42/D30, M73/V56, R105‘/P81‘ 
Unique H7’, P62, Q63 





















R10’/8’, D41/29, I64/47 
H65/G48, V104‘/T80’, R105‘/P81‘, G106‘/V82’ 
Q63 
R10’/8’, L35’/23‘, D37’/25’, G39/27, D41/29, G66/49, 
I42/030,144/V32, H65/G48, M73/V56, A100/L76 
A40/28, D41/29,16-6/49, I67‘/50’, I108/84 
H65/G48, V104‘/T80’, R105’/P81’,/V82’, S107‘/N83’ 
R10‘/8’, L35’/23‘, D37’/25’, D37/25,  G39/27, G66/49, 
H65’/G48’, V104/T80, R105/P81, G106/V82, S107/N83 




142’/D30r,’144’7V32‘, H65’/G48’, M73‘/V56‘, A100‘/ 
A40‘/28‘, D41‘/29‘, 164’/47’, G66’/49’, 167/50, I108’/84’ 




g;Q/8, L35/23, G39‘/27’, 041  ’/29‘, 164‘/47’, G66‘/49‘, 
I67’/50‘, I108/84, R111’/87’ 
’ The amino acid residues that  are  not conserved or unique to  the AMV/RSV PR  (not present in the HIV-1 PR) or are conserved between 
*Amino acid residues in  the second subunit of the dimer are indicated by a prime. The first  amino acid number refers to AMV/RSV, 
the AMV/RSV and HIV-1 PR subsites as indicated. 
whereas the second refers to HIV-1 PR.  The underlined (italicized) residues are involved in substrate main  chain hydrogen bond formation. 
AMV/RSV PR.  For example, the  NC-PR  analogue  with Gly 
at P4 is a reasonable substrate for HIV-1 PR but not for 
AMV/RSV PR, where the kcat/& is reduced to 10% of that 
with Pro. 
Substitution of Leu or  Phe  for Pro in the  P4  position of 
the  NC-PR  substrate  resulted  in a substantial loss in  binding 
and a small decrease in  the  catalytic  rate by HIV-1 P R  (Table 
I).  These  substitutions  also  resulted  in a substantial decrease 
in cleavage by AMV/RSV PR.  This  result suggests that large 
hydrophobic  residues are  not  tolerated  in  the  P4  position by 
either enzyme,  which is consistent  with  the  presence of several 
polar residues in  the  S4  subsite (Fig.  2a, Table IV). In  contrast, 
when polar residues were substituted  into  the  P4  position,  all 
of the  peptides were substrates,  although  the kccat/& values 
varied depending  upon  the  amino acid substituted  (Tables I 
and 11). It is  worth  noting  that  introduction of His  in  the  P4 
position of the  NC-PR  substrate  increased  its  relative KM for 
HIV-1  PR  but decreased it for AMV/RSV P R  (Tables I and 
11). This  result  can be explained by the  presence in S4 of Ile- 
42 in AMV/RSV PR,  as  compared with  Asp-30 in  HIV-1  PR. 
Molecular modeling suggests that Asp-30 of HIV-1 P R  can 
form  an ionic interaction  with  His  in  the  P4  substrate posi- 
tion, which would improve its KM. This has been tested 
experimentally by substituting Asp for Ile-42 in  the AMV/ 
RSV  PR.  The  resulting enzyme  showed  a 2-fold increase  in 
efficiency of cleavage of the  His-P4  substituted  NC-PR  sub- 
strate,* similar to that observed for HIV-1 PR (Table I). 
Tozser et al. (13) found  comparable  results  in  their  analysis 
of HIV-1  and  HIV-2  PRs, i.e. most  P4  analogues  tested were 
utilized as  substrates with the exception of those with  larger 
hydrophobic residues. These studies used a peptide with a 
totally  different  sequence from NC-PR. Also, they observed 
that amino acids frequently found in turns in the three- 
dimensional  structure of proteins (Gly, Pro,  Asn), when sub- 
stituted  in  the  P4  position, produced good substrates for HIV- 
1 P R  (13). 









FIG. 1. A schematic representation of the AMV/RSV NC- 
PR substrate, PAVSLAM, from P4-P3' in the S4-S3' sub- 
sites of PR. The relative size of each  subsite  is indicated approxi- 
mately by the area enclosed by the curued line around each substrate 
side chain. Protease residues forming the subsites are shown for those 
that differ between the AMV/RSV and HIV-1  PRs. The AMV/RSV 
PR residue is shown outside the parentheses, whereas the HIV-1 PR 
residue is shown in the parentheses. Most of the residues contribute 
to more than one adjacent subsite, and  this is indicated by the position 
of the label. 
Subsite S3"The  S3 subsites of HIV-1  and AMV/RSV PR 
consist of relatively open and deep pockets that  are near the 
surface (Fig. 2b). This allows side chains of amino acids in 
the  P3 position freedom of movement to either  interact with 
hydrophobic residues near the  S1 subsite or polar residues at 
the surface of the enzyme. Thus,  the  S3 subsite  can accom- 
modate both polar and nonpolar residues. This is consistent 
with the presence of both polar and hydrophobic amino acids 
in  the  P3 position of the known AMV/RSV and HIV-1 gag 
and pol cleavage sites  (Table 111). This ability of the  S3 subsite 
to accommodate a variety of residues is also seen with substi- 
tutions in the  P3 position of the  NC-PR peptide (Tables  I 
and 11). Replacing Ala with larger amino acids that are 
charged (His, Arg), polar (Asn),  or nonpolar (Phe), resulted 
in a 2-7.5-fold increase in efficiency of cleavage by AMV/ 
RSV PR, depending upon the amino acid substituted. The 
increased efficiency was due to both an improvement in 
binding and  an increase in catalytic rate (Table 11). In con- 
trast, substitutions of smaller residues, such as glycine or 
proline, were not  tolerated  as well. 
Although AMV/RSV PR exhibited increased activity with 
many of the P3-modified peptides, HIV-1 PR retained  about 
the same level of activity with all the substitutions  (Table I). 
These  results may be explained, in part, by the fact that  the 
HIV-1 S3 subsite is more open than  that of AMV/RSV due 
to  the presence of Pro-81 in HIV-1 PR, as compared with 
Arg-105 at the structurally identical position in the avian 
enzyme (Fig. 2b). This difference would reduce the possibility 
for additional van der Waal interactions in the HIV-1 S3 
subsite, thus precluding changes in  catalytic efficiency. The 
&fold preference for Phe in P3 by  AMV/RSV PR relative to 
HIV-1 PR can be explained by the presence of Gly-106 in 
AMV/RSV PR,  as compared with Val-82 in the analogous 
position of HIV-1 PR. Val is at the top of the HIV-1 S3 
subsite pointing into the pocket so that it could sterically 
interfere with the binding of a large amino acid residue such 
as  Phe (12). This steric hindrance would not be a problem 
with Gly in  the AMV/RSV subsite. The AMV/RSV PR  S3 
subsite also contains 2 basic residues, His-65 and Arg-105, 
not found in the HIV-1 S3  subsite.  These residues confer on 
portions ofthe avian subsite a greater degree  of hydrophilicity. 
However, the charged groups of these amino acids are  prob- 
ably not providing strong ionic interactions with substrate. 
This is inferred from the fact that calculation of the relative 
energy of interaction from the steady state kinetic data for 
the P3-substituted  NC-PR peptide substrates indicates that 
there is only a 1-1.3 kcal/mol improvement in the energy of 
interaction for the best  substrates. Ionic interactions would 
contribute an additional 4-5 kcal/mol of energy to  the  inter- 
action of this substrate with PR, which  would correspond to 
increases in the catalytic efficiency of 40-50-fold (26, 27). 
Such large changes in the catalytic efficiencies are not ob- 
served (Table 11). The magnitude of change observed here is 
more consistent with small perturbations in side chain van 
der Waal or weak hydrogen bond interactions.  This suggests 
that  the aliphatic side chain of Arg-105 in AMV/RSV PR 
may have an  important hydrophobic role in defining the  S3 
subsite. In agreement with our results, Konvalinka et al. (28) 
found that HIV-1 PR will accept a variety of residues in the 
P3 position, whereas Strop et al. (29) report that  the AMV 
enzyme has  a preference for large polar or nonpolar residues 
at this position. 
It is worth noting that in our kinetic studies of PR, we have 
not discussed the differential free energy of binding as de- 
scribed by Fersht  (27).  These calculations assume that there 
is no significant conformational change of the enzyme upon 
substrate binding. This is not  the case for the retroviral PR, 
where comparison of the crystal  structures of HIV-1 PR in 
the absence and presence of inhibitor  (5) shows that  the flaps 
are very flexible. They apparently must open to allow the 
polyprotein substrate to enter  the binding site  and  then close 
to dock the substrate  and  restrain the scissile bond prior to 
catalysis (30). After cleavage, the flaps again move to release 
the products. In  addition, we have exchanged small residues 
in the natural NC-PR substrate, in many cases, for larger 
ones. This may cause a sufficient rearrangement of the side 
chains in the  PR substrate-binding pocket that  it invalidates 
assumptions made by Fersht (27) in derivation of the rela- 
tionship between catalytic efficiency and free energy of bind- 
ing. 
Subsite S2"The S2 subsites of both PRs (Fig. 2c) are 
sterically restricted, as compared with S4 and S3 and are 
predicted to accommodate hydrophobic residues (Table IV). 
Mostly small or intermediate sized hydrophobic residues are 
found in the P2 position of natural gag and pol cleavage sites 
(Table 111), with the exception of Phe in one AMV/RSV site 
and Asn in four of the HIV-1  sites.  This ability of HIV-1 PR 
to accommodate a more polar residue may be related to  the 
presence of Asp-30 in the S2 subsite of HIV-1, as compared 
with Ile-42 at  the analogous location in AMV/RSV PR. Also, 
the presence of Val-32 in HIV-1 PR,  as compared with Ile-44 
in AMV/RSV PR, allows for a larger side chain at P2. 
The requirement in S2 for small hydrophobic substrate 
residues is consistent with the results of replacement of  Val 
at  the P2 position of the  NC-PR peptide substrate with larger 
hydrophobic residues (Leu or Trp); there is a significant 
decrease in the catalytic efficiency of AMV/RSV PR (Table 
11). Substitution of a polar residue (Ser) or a large hydrophobic 
residue (Trp) in P2 caused an increase in KM with only a 
modest change in kcat. In  contrast,  the  Leu-substituted  ana- 
logue  was  more efficiently cleaved by HIV-1 PR, reflecting a 
small improvement in binding. This difference can be ex- 
plained by the presence of Ile-44 in AMV/RSV, as compared 
with Val-32 in HIV-1  PR.  These residues have been shown 
to determine the selection of amino acids in the P2 (and P2') 
substrate positions by exchanging Val for Ile-44 in AMV/ 
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FIG. 2. Stereo views of subsites 54-53' of AMV/RSV and HIV-1 proteases. The HIV-1 PR atomic coordinates, shown by dashed 
lines, are from the crystal  structure  7HVP (19) with inhibitor JG365. The RSV PR coordinates are from the crystal  structure of Jaskolski et 
al. (17) with residues 61-69  of the flaps from modeling (12) and  are shown in thin continuous lines. Note that RSV PR residues His-7, Pro- 
62, and Gln-63 have no corresponding residues in HIV-1 PR.  The model substrate is shown in thicker lines. In each view, the substrate side 
chain is approximately vertical, and  the related subsites, S3  and S3', S2 and SZ', and S1 and SI', are shown in very similar orientations. a, 
subsite S4 with Pro at  P4; b, subsite S3 with Ala at  P3; c, subsite S2 with Val a t  P2; d, subsite S1 with Ser in PI; e, subsite SI' with Leu at 
PI'; f ,  subsite S2' with Ala at P2'; g, subsite S3' with Met a t  P3'. 
RSV PR.' The wild type AMV/RSV PR prefers valine in the primary  determinant  in selection of amino acids in the differ- 
P2 position of the  NC-PR  substrate, whereas HIV-1 PR and  ent  substrate positions. Equine infectious anemia virus PR 
a mutant RSV PR containing Val in the 52 subsite prefer also shows a preference for small hydrophobic residues at P2, 
Leu. Thus,  the removal of a methyl group in  the side chain of which correlates with the presence of Thr 30 in subsite S2 in 
the  substrate can be compensated for by the addition of a the place occupied by Asp-30 in HIV-1 PR.4 Tozser et al. (24) 
methyl group to the side chain of the amino acid in the 
enzyme subsite. This suggests that optimization of van der 'Weber, I., TozsBr, J., Wu, J., Friedman, D., and Oroszlan, S .  
Waal interactions in the individual enzyme subsites is a (1993) Biochemistry 32, 3354-3362. 
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have reported kinetic measurements for HIV-2 PR, which has 
Ile at position 32 instead of the Val present in HIV-1  PR. A 
similar compensation in  substrate for the gain of a methyl 
group in the amino acid at position 32 in HIV-2 was not 
observed. This was attributed  to an unfavorable steric  inter- 
action of Pro in P1‘ with the 8-branched side chains such as 
Val in P2. 
AS with S3 and S4, the S2 subsite of AMV/RSV PR is 
predicted to be smaller than  that of HIV-1 PR due to  the 
presence of Ile-44 and Ile-42 in AMV/RSV PR,  as compared 
with Val-32 and Asp-30 in HIV-1 PR (Fig.  2c). Thus,  although 
neither enzyme preferred polar or large hydrophobic residues 
in P2, the HIV-1 PR was more tolerant of substitutions than 
AMV/RSV PR. Table I1 shows lower relative bak/KM values 
for AMV/RSV PR  than HIV-1 PR with the same analogues 
(Table I). The ability of HIV-1 PR  to accommodate various 
amino acids in the S2 subsite, as well as  in  the  S3  and S4 
subsites, may explain why previous studies of HIV-1 PR 
demonstrated an expanded substrate selectivity range, as 
compared with AMV/RSV PR (20). 
Konvalinka et al. (28), using a different peptide as  a  starting 
point, found a relatively strong preference for Val or Ile in 
the  P2 position for HIV-1  PR. Using the same enzyme and 
pol precursor proteins as substrate, Jupp et al. (31) found a 
preference for Val, as compared with Gly in this position. 
Strop et al. (29), using myeloblastosis-associated virus PR, 
found a preference for small hydrophobic residues in S2, 
which is consistent with the preference for Val in P2 of NC- 
PR. 
Subsite SI-The S1 subsites of both  HIV-1  and AMV/RSV 
PR, like the  S3 subsites, consist of relatively large and deep 
pockets (Fig. 2d).  They also include the catalytic  aspartic acid 
residues. However, the  S1 subsites are mainly hydrophobic 
and embedded inside the protein. It is therefore  not  surprising 
to find hydrophobic residues at this position in  the  natural 
gag andpol polyprotein cleavage sites  (Table 111). Also, similar 
to  the more open S3 subsite, substitution of large hydrophobic 
amino acids in the P1 position increases the turnover  rate of 
substrate. For instance, exchanging Trp,  Phe,  or  Tyr for Ser 
in the P1 position of the NC-PR  substrate resulted in 26, 17, 
and 19-fold increases, respectively, in efficiency of cleavage 
of these  substrates by AMV/RSV PR (Table 11). These  in- 
creases are due to favorable changes in both binding and  rate 
of catalysis. Among the different  NC-PR analogues analyzed, 
substitution of amino acids in P1 produced the largest in- 
creases in  catalytic efficiency. This probably reflects the large 
size of the  S1 subsite and  its closeness to  the scissile bond. 
The finding that substitution of AMV/RSV Val-104 with 
HIV-1 Thr or AMV/RSV Ser-107 with HIV-1 Asn signifi- 
cantly increased the  rate of catalysis by the AMV/RSV PR 
without changing the  substrate specificity’ is consistent with 
the above argument. The HIV-1 PR also showed an increase 
in activity with Trp substituted in P1, but only 8-f0ld, whereas 
Leu in this  substrate position resulted in  a 13-fold increase in 
the  rate of catalysis. Thus  the HIV-1 enzyme prefers medium- 
sized hydrophobic residues in P1. This preference can be 
explained by the presence of Val-82 in HIV-1 PR, as compared 
with Gly-106 in AMV/RSV PR (12). The Val side chain 
points down into  the subsite pocket. Thus, in contrast  to  the 
534, S3, and S2 subsites, the S1 subsite of HIV-1 PR is smaller 
than that of AMV/RSV PR (see Fig. 2 4 .  Several reports 
have noted the importance of having a large hydrophobic 
residue, particularly a Leu, in P1 (21, 29-31). This feature is 
also reflected in the choice of naturally occurring P1 residues 
in  the case of HIV-1  (Table 111). 
Interestingly, polar or charged residues substituted at  the 
P1 position (His, Arg, and Glu) resulted in better  substrates 
for AMV/RSV PR than for the HIV-1 enzyme. This may 
reflect the fact that  the AMV/RSV S1 subsite is more polar 
than  that of HIV-1 PR due to  the presence of Arg-105 and 
His-65. In contrast, Gly substitution was tolerated far  better 
Subsites SI ‘-53‘”Because of the symmetrical structure of 
the  PR homodimer, the Sl’-S3’ subsites utilize many of the 
same amino acids that form the  Sl-S3 subsites. Thus, one 
would expect the  properties of the “prime” subsites to mimic 
those described for Sl-S3. However, the peptide substrate is 
asymmetric and  binds in an asymmetric manner. Therefore, 
the properties of the prime subunit of the enzyme are different 
from those of the “nonprime”  subunit. One difference appears 
to be that  the Sl’-S3’ subsites are smaller. This can be seen 
directly by comparing the stereo  picture of the subsite S3 to 
that of S3’ and of subsite S2 to  that of S2’ (Fig. 2, b-g and c- 
f, respectively). In  the case of S1 and Sl’, measurements were 
made of the distance between the C, atoms of residues 105 
and 106 in AMV/RSV PR and 81 and 82 in HIV-1 PR to the 
corresponding substrate positions.* It was found that these 
distances were 0.7-1.5 and 1.3-1.6 A closer to P1’ than to P1, 
respectively. Thus, changes in the Pl’-P3’ amino acids to 
larger residues usually resulted in decreased catalytic efficien- 
cies for both PRs (Tables I and 11). The effect of the size 
difference between the related prime and nonprime subsites 
was also observed in the analysis of a AMV/RSV p2-p10 
peptide substrate/inhibitor (20). Its ability to inhibit the  PR 
activity was related, in part,  to  the steric properties of amino 
acid side chains in the P2’ and  P3’ positions and  their ability 
to fit into  the relatively small S2‘ and S3’ subsites (20). 
None of the amino acids substituted in the P1’ position of 
the NC-PR  substrate improved the efficiency of cleavage by 
either  PR,  as compared with wild type. This is in contrast  to 
the large increases in  the activity observed for both PRs when 
the same substitutions were placed in  the P1 position. The 
amino acids tested included polar (Arg, Gln, Glu), large hy- 
drophobic (Phe), or no side chain (Gly). AMV/RSV PR 
tolerated polar residues in the P1’ position of the NC-PR 
substrate  (such  as Arg) better than HIV-1 PR (Tables I and 
11). This is also seen in the amino acids found in the natural 
gag and pol cleavage sites listed in Table 111, in  which three 
of the avian sites  contain  either  Ser  or  Thr. Like the  struc- 
turally related S1 subsite, the avian S1’ subsite  is more polar 
due to  the presence of His-65’ and Arg-105, as compared with 
Gly-48’ and Pro-81 in HIV-1 PR. In referring to PR, the 
prime amino acids are derived from the second subunit of the 
PR dimer. Substitution of His-65 and Arg-105 with Gly and 
Pro, respectively, produces AMV/RSV PRs  that no longer 
tolerate polar amino acid residues in the  P1’ position of the 
NC-PR peptide substrate (12). 
The more hydrophobic nature of the HIV-1 S1’ subsite 
presumably accounts for the activity of the NC-PR peptide 
with Phe  substituted in P1’ (Table  I). However, HIV-1 PR is 
less active with this substrate than with wild type, which 
contains Leu in this position. The reduced activity of the 
HIV-1 PR may be due to steric  hindrance between Val-82 and 
Phe in PI’ (Fig. 2e). Substitution of  Gly in P1’ resulted in a 
20-fold and at least 1000-fold decrease in efficiency of cleavage 
of the NC-PR substrate by HIV-1 and AMV/RSV PRs, 
respectively. This  result verifies the importance of side chain 
interactions at Pl’. 
The S1’ subsites for both enzymes are predicted to accom- 
modate medium-sized hydrophobic residues best. Although 
few such residues were tested  in the context of the NC-PR 
peptide, they were tested in the context of the AMV/RSV p2- 
by HIV-1  PR. 
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p10 peptide substrate (PYVG-SGLY) (20). The substitution 
of Ser in PI’ with Ala produced an active substrate with an 
efficiency of cleavage equivalent to the wild type NC-PR 
peptide substrate (20). Substitution of the larger Leu in P1’ 
improved the efficiency of specific cleavage by the AMV/RSV 
PR  an additional 2-fold, due primarily to  an increase in the 
rate of catalysis. 
Changes in kcat seem to be more evident for substitutions 
on the prime side relative to  the nonprime side of both the 
NC-PR  and  the p2-p10 (20) peptide substrates. The kinetic 
mechanism for HIV-1 PR described by Hyland  et al. (32, 33) 
proposes the existence of several potentially rate-limiting 
steps after substrate binding. This includes conformational 
changes, such as opening and closing of the  PR flaps, forma- 
tion of the amide-hydrate intermediate, or product release 
itself. Our studies cannot identify the rate-limiting step. 
Therefore, when the kat varies, it is not clear if this reflects 
modulation of the  rate of the existing rate-limiting  step or a 
change to a different rate-limiting  step in the reaction. 
The S2’ subsite, like S2, is predicted to accommodate small 
hydrophobic residues (Fig. 2f). The same series of amino acids 
tested  in the P2 position of the  NC-PR  substrate were intro- 
duced into the P2’ position. Every substitution listed in 
Tables I and I1 resulted in a significant loss in the efficiency 
of cleavage by both AMV/RSV and HIV-1 PRs. Although 
AMV/RSV PR preferred the wild type Ala over any other 
substitution, HIV-1 PR was somewhat more tolerant than 
AMV/RSV of changes in P2’ to Ser, Gly, or Leu. Trp, 
however,  is too large for either PR  to fit in the S2‘ subsite. 
Tozser et al. (24) observed that Val and Leu, medium-sized 
hydrophobic residues, produced the best substrates for HIV- 
1 and -2 PRs when substituted in P2’, in  qualitative agree- 
ment with the results shown here. 
Substitution of the small hydrophobic residues Ala or Val 
for Gly in  the P2’ position of the AMV/RSV  p2-p10 peptide, 
produced substrates that were  2-3-fold  more efficiently 
cleaved by  AMV/RSV PR  than a P2’  Leu-substituted p2-plO 
peptide (20). This is consistent with the hypothesis that  the 
S2’ subsite prefers small hydrophobic residues. Similar  results 
were obtained by Margolin et al. (34) when substitutions were 
made in the P2’ position of the HIV-1 MA-CA processing 
site, Le. a preference for hydrophobic residues, and low or no 
cleavage  when substitution of Gly or Trp was made in  this 
position. With  their  substrate, however, Ile had a higher kcat 
than Ala or Leu, which further demonstrates the effect of 
context on substrate selection by PR. In studies with the 
myeloblastosis-associated virus PR,  Strop  et al. (29) reported 
an apparently symmetrical requirement for small hydrophobic 
residues in both P2 and  P2’  and large hydrophobic residues 
in P1 and Pl’. Although our results indicate similar prefer- 
ences, the  substrate side chain specificities are  not identical 
in  either the 52 subsite, as compared with S2’ or in  the  S1 
subsite, as compared with SI’. 
The AMV/RSV PR,  but  not the HIV-1 PR, was stimulated 
when Tyr replaced Met in the P3’ position of the NC-PR 
substrate. As presented in the discussion of the  S3 subsite, 
this difference is probably related to  the presence of Gly-106 
in AMV/RSV PR and Val-82 in HIV-1 PR (Fig. 2g). The 
other substitutions tested at P3‘, Leu, Asn, Gly and Asp, 
caused large reductions in activity for  both enzymes. 
The binding pockets of HIV-1 and HIV-2 PRs  are predicted 
to contain four conservative differences (25). Crystallographic 
data for the HIV-2 enzyme are  not publicly available at  this 
time. However, it  is reasonable to assume that given the higher 
degree of homology between the HIV-1  and HIV-2 PRs,  as 
compared with that of HIV-1  and AMV/RSV PR,  the residues 
comprising the substrate-binding pocket would be closely 
related. The few reports that exist (13,24), as well as our own 
unpublished data, indicate that  the HIV-1 and HIV-2 PRs 
have very similar substrate specificities. 
Contribution of Amino Acid Side C h i n  Interactions to Bind- 
ing of Substrate-The peptides with Gly inserted into the 
different positions were generally poor substrates with either 
PR.  This was the case even for substitutions at  the  P3 or P1 
positions, where the broadest range of side chains were ob- 
served. When comparing the two enzymes, however, HIV-1 
PR was more tolerant of glycine substitutions than AMV/ 
RSV PR. Apparently HIV-1 PR is somewhat less dependent 
upon side chain interactions than the larger, and perhaps 
more flexible, AMV/RSV PR.  This difference in dependence 
on side chain interactions can be seen by comparing the 
catalytic efficiency of each substrate relative to  the catalytic 
efficiency of the comparable Gly-modified substrate. For ex- 
ample, Leu at P1 is 19.3-fold better than Gly for  HIV-1  PR, 
whereas it is 85-fold better for AMV/RSV PR. Overall, the 
side chains have a larger contribution to  the catalytic effi- 
ciency for AMV/RSV than for HIV-1  PR. 
General Comments-There  is interaction between the  ad- 
jacent subsites of the enzyme-binding cleft. Residues that 
produce good substrates at certain positions in one peptide 
sequence may not work  well in  other sequences. For example, 
although Leu and Ser occur in the P2’ position of natural 
AMV/RSV PR substrates  (Table 111), the same substitutions 
are  not favored in the context of the NC-PR  substrate  (Tables 
I and 11). Tritch  et al. (22) tried to mix features from various 
efficiently cleaved substrates and found that  the combinations 
tended to be very poor substrates. Thus  substrate selection 
by PR must be based on recognition of all 7 amino acids of 
the  substrate simultaneously. 
Drug Design and Viral Resistame-Rational design of in- 
hibitors of HIV-1 PR is aided by structural data from the 
large number of co-crystal structures that have been deter- 
mined. In some cases, new inhibitors have been designed 
based upon structural information (7, 11). Analysis of HIV-1 
PR-inhibitor  structures  has suggested that substrate  or inhib- 
itor binding has two components (25). 1) The main chain 
C=O and NH groups of peptides or peptidic inhibitors have 
hydrogen bond interactions with PR residues. These are 
highly conserved among the different crystal structures‘ and 
are independent of amino acid sequence. Molecular energy 
minimization calculations suggest that main chain atoms 
contribute 56 to 68% of the total PR-inhibitor interaction 
energy? This suggests that  PR residues that form  hydrogen 
bond interactions with main chain  atoms of the inhibitor will 
be conserved and  are less likely to  mutate in selection of drug 
resistant viruses. Thus,  it is important to include potential 
hydrogen bond donors and acceptors for these  interactions in 
the design of inhibitors. 2) Each side chain of the  substrate 
or peptidic inhibitor lies in successive subsites from S4 to S3‘ 
formed by PR residues. This component is dependent upon 
the amino acid sequence of a substrate  (or  inhibitor)  and is 
being studied by the steady state kinetic measurements pre- 
sented here and by other laboratories. Amino acids that 
provide tight binding at  a  particular position and form good 
PR substrates  are predicted to also form effective inhibitors 
when these amino acids are placed at  the same position in an 
inhibitor. This has been demonstrated with modifications of 
the AMV/RSV  p2-p10 inhibitory peptide (20), in which a 40- 
fold improvement in Ki was observed when Gly at P1 was 
replaced by Trp  and  Tyr  at  P3 was replaced by Phe.  These 
A. Gustchina, personal communication. 
A. Gustchina and C. Sansom, personal communication. 
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specific substitutions were chosen based on the kinetic data 
presented herein. 
Finally, alterations in residues forming the PR subsites 
have been shown to effect the binding of substrates (12, 20). 
Even a small change in a  particular subsite might be sufficient 
to reduce the affinity for a specific inhibitor. We  would thus 
predict that the residues that we have proposed as being 
important  determinants in substrate selection in the various 
PR subsites would  be potential  sites for selection of natural 
mutations that will produce drug-resistant phenotypes in 
AIDS patients treated with inhibitors of HIV PR. These 
residues would include HIV Val-32, Pro-81, and Val-82 and 
perhaps Asp-30 and/or Gly-48. 
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